A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53

Human Pathology

Volumn 42, Issue 8, 2011, Pages 1103-1111

  Väisänen, Anne ^a   Kuvaja, Paula ^a,b   Kallioinen, Matti ^a   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Gelatinase; Ki67; Matrix metalloproteinase; Matrix metalloproteinase inhibitor; p53

Indexed keywords

GELATINASE A; GELATINASE B; KI 67 ANTIGEN; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FINLAND; HUMANS; KI-67 ANTIGEN; MALE; MATRIX METALLOPROTEINASE 2; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79960404098     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.11.013     Document Type: Article

References (27)

1. Balch C.M., Soong S.J., and Gerschenwald J.E. Prognostic factors analysis of 17600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 2001 3622 3634 (Pubitemid 32786275)
2. Gould Rothenberg B.E., Bracken M.B., and Rimm D.L. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis J Natl Cancer Inst 101 2009 452 474
3. Björklund M., and Koivunen E. Gelatinase-mediated migration and invasion of cancer cells Biochim Biophys Acta 1755 2005 37 69 (Pubitemid 40720240)
4. Deryugina E.I., and Quigley J.P. Matrix metalloproteinases and tumor metastasis Cancer metast Rev 25 2006 9 34 (Pubitemid 43723979)
5. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and MMP-9) and their natural inhibitors as prognostic indicators in solid cancers Biochim 87 2005 287 297 (Pubitemid 40387607)
6. Talvensaari-Mattila A., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma Br J Cancer 9 2003 1270 1275 (Pubitemid 37363416)
7. Vasala K., Paakko P., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer Urology 62 2003 952 957 (Pubitemid 37421256)
8. Väisänen A., Kallioinen M., Taskinen P.J., and Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72kDa type IV collagenase) in primary skin melanoma J Pathol 186 1998 51 58 (Pubitemid 28407488)
9. Väisänen A., Kallioinen M., and Turpeenniemi-Hujanen T. Comparison of the prognostic value of matrix metalloproteinases MMP-2 and -9 in cutaneous melanoma Hum Pathol 39 2008 77 85
10. Baker A.H., Edwards D.R., and Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities J Cell Sci 115 2002 3719 3727 (Pubitemid 35203598)
11. Jiang Y., Goldberg I.D., and Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer Oncogene 21 2002 2245 2252 (Pubitemid 34311378)
12. Valente P., Fassina G., and Melchiori A. TIMP-2 overexpression reduces invasion and angiogenesis and protect B16F10 melanoma cells from apoptosis Int J Cancer 75 1998 246 253 (Pubitemid 28100066)
13. Airola K., Karonen T., and Vaalamo M. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas Br J Cancer 80 1999 733 743 (Pubitemid 29209836)
14. Hoffman U.B., Houben R., and Bröckner E.B.M. Role of matrix metalloproteinases in melanoma cell invasion Biochim 87 2005 307 314 (Pubitemid 40387609)
15. van Dienst P.J., Brugal G., and Baak L.P. Proliferation markers in tumours: interpretation and clinical value J Clin Pathol 51 1998 16 24
16. Straume O., Sviland L., and Akslen L.A. Loss of nuclear p16 protein expression correlates with increased tumour cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma Clin Cancer Res 6 2000 1845 1853 (Pubitemid 30305081)
17. Moretti S., Spallanzani A., and Chiarugi A. Correlation of Ki67 expression in cutaneous primary melanoma with prognosis in a prognostic study: different correlation according to thickness J Am Acad Dermatol 44 2001 188 192 (Pubitemid 32172178)
18. Ilmonen S., Hernberg M., and Pyrhönen S. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma Melan Res 15 2005 375 381 (Pubitemid 41558947)
19. Ladstein R., Bachmann I., and Straume O. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma BMC Cancer 10 2010 140
20. Essner R., Kuo C., and Wang H. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites Cancer 82 1998 309 316 (Pubitemid 28060247)
21. Ohsie S., Sarantopoulos P., Cochran A., and Binder S.W. Immunohistochemical characteristics of melanoma J Cutan Pathol 35 2008 433 444 (Pubitemid 351519417)
22. Soares de Sa B.C., Fugimori M.L., and de Cassia Braga Ribeiro K. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas Melan Res 19 2009 135 141
23. Ketcham A.S., Moffat F.L., and Balch C.M. Classification and staging C.M. Balch, A.A. Houghton, G.W. Milton, A.J. Sober, S.J. Soong, Cutaneous melanoma 1992 J.B. Lippincott Philadelphia 213 220
24. Carlson J.A., Ross J.S., and Slominski A. Molecular diagnostics in melanoma J Am Acad Dermatol 52 2005 743 775 (Pubitemid 40614638)
25. Bian J., and Sun Y. Transcription activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase-2) promoter Mol Cell Biol 17 1997 6330 6338 (Pubitemid 27451177)
26. Nakopoulou L., Giannopoulou I., and Lazaris A.C.H. The favourable prognostic impact of tissue inhibitor of matrix metalloproteinase-1 protein overexpression in breast cancer cells APMIS 111 2003 1027 2003
27. Hoffman U.B., Westphal J.R., and Zendman A.J.W. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type I matrix metalloproteinase (MT1-MMP) correlate with melanoma progression J Pathol 191 2000 245 256 (Pubitemid 30441247)